These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34239813)

  • 1. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.
    Kudo M; Lim HY; Cheng AL; Chao Y; Yau T; Ogasawara S; Kurosaki M; Morimoto N; Ohkawa K; Yamashita T; Lee KH; Chen E; Siegel AB; Ryoo BY
    Liver Cancer; 2021 Jun; 10(3):275-284. PubMed ID: 34239813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
    Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
    J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.
    Merle P; Kudo M; Edeline J; Bouattour M; Cheng AL; Chan SL; Yau T; Garrido M; Knox J; Daniele B; Breder V; Lim HY; Ogasawara S; Cattan S; Chao Y; Siegel AB; Martinez-Forero I; Wei Z; Liu CC; Finn RS
    Liver Cancer; 2023 Sep; 12(4):309-320. PubMed ID: 37901200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
    Chung HC; Kang YK; Chen Z; Bai Y; Wan Ishak WZ; Shim BY; Park YL; Koo DH; Lu J; Xu J; Chon HJ; Bai LY; Zeng S; Yuan Y; Chen YY; Gu K; Zhong WY; Kuang S; Shih CS; Qin SK
    Cancer; 2022 Mar; 128(5):995-1003. PubMed ID: 34878659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
    Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Dai H; Niu C; Li J; Guo J
    Front Immunol; 2022; 13():882471. PubMed ID: 36304457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
    Qin S; Chen Z; Fang W; Ren Z; Xu R; Ryoo BY; Meng Z; Bai Y; Chen X; Liu X; Xiao J; Ho GF; Mao Y; Wang X; Ying J; Li J; Zhong W; Zhou Y; Siegel AB; Hao C
    J Clin Oncol; 2023 Mar; 41(7):1434-1443. PubMed ID: 36455168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
    Verset G; Borbath I; Karwal M; Verslype C; Van Vlierberghe H; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline J; Cattan S; Kudo M; Cheng AL; Ogasawara S; Daniele B; Chan SL; Knox JJ; Qin S; Siegel AB; Chisamore M; Hatogai K; Wang A; Finn RS; Zhu AX
    Clin Cancer Res; 2022 Jun; 28(12):2547-2554. PubMed ID: 35421228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.
    Im SA; Cortes J; Cescon DW; Yusof MM; Iwata H; Masuda N; Takano T; Huang CS; Chung CF; Tsugawa K; Park YH; Matsumoto K; Inoue K; Kwong A; Loi S; Fu W; Pan W; Karantza V; Rugo HS; Schmid P
    NPJ Breast Cancer; 2024 Sep; 10(1):79. PubMed ID: 39266535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in
    Ferrucci PF; Di Giacomo AM; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Stephens R; Svane IM; Lotem M; Abu-Amna M; Gasal E; Ghori R; Diede SJ; Croydon ES; Ribas A; Ascierto PA;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
    Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
    ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
    Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J
    Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.
    Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA
    Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
    J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
    Rodríguez-Abreu D; Powell SF; Hochmair MJ; Gadgeel S; Esteban E; Felip E; Speranza G; De Angelis F; Dómine M; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Kurata T; Yang J; Pietanza MC; Souza F; Garassino MC
    Ann Oncol; 2021 Jul; 32(7):881-895. PubMed ID: 33894335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
    Lau G; Abou-Alfa GK; Cheng AL; Sukeepaisarnjaroen W; Van Dao T; Kang YK; Thungappa SC; Kudo M; Sangro B; Kelley RK; Furuse J; Park JW; Sunpaweravong P; Fasolo A; Yau T; Kawaoka T; Azevedo S; Reig M; Assenat E; Yarchoan M; He AR; Makowsky M; Gupta C; Negro A; Chan SL
    J Hepatol; 2024 Jul; ():. PubMed ID: 39089633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407.
    Cheng Y; Zhang L; Hu J; Wang D; Hu C; Zhou J; Wu L; Cao L; Liu J; Zhang H; Sun H; Wang Z; Gao H; Sun Y; Li B; Hu X; Schwarzenberger P; Paz-Ares L
    JTO Clin Res Rep; 2021 Oct; 2(10):100225. PubMed ID: 34661177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
    Paz-Ares L; Vicente D; Tafreshi A; Robinson A; Soto Parra H; Mazières J; Hermes B; Cicin I; Medgyasszay B; Rodríguez-Cid J; Okamoto I; Lee S; Ramlau R; Vladimirov V; Cheng Y; Deng X; Zhang Y; Bas T; Piperdi B; Halmos B
    J Thorac Oncol; 2020 Oct; 15(10):1657-1669. PubMed ID: 32599071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
    Sugawara S; Tanaka K; Imamura F; Yamamoto N; Nishio M; Okishio K; Hirashima T; Tanaka H; Fukuhara T; Nakahara Y; Kurata T; Katakami N; Okada M; Horinouchi H; Udagawa H; Kasahara K; Satouchi M; Saka H; Tokito T; Hosomi Y; Aoe K; Kishi K; Ohashi K; Yokoyama T; Adachi N; Noguchi K; Schwarzenberger P; Kato T
    Cancer Sci; 2023 Aug; 114(8):3330-3341. PubMed ID: 37183528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.